Skip to main content
. 2020 Jun 19;69(12):2513–2522. doi: 10.1007/s00262-020-02637-1

Fig. 2.

Fig. 2

PFS and OS among lung carcinoma according to baseline NLR (a, b) and NLR variations between the first and the fourth administration (c, d). a Is referring to the PFS of patients of the lung carcinoma cohort according to the baseline NLR value (below or above the median NLR baseline value in the lung carcinoma cohort). b Is referring to the OS of patients of the lung carcinoma cohort according to the baseline NLR value (below or above the median NLR baseline value in the lung carcinoma cohort). c Is referring to the PFS of patients of the lung carcinoma cohort according to the NLR variation between the first and the fourth nivolumab administration. d Is referring to the OS of patients of the lung carcinoma cohort according to the NLR variation between the first and the fourth nivolumab administration